|
AstraZeneca PLC on Thursday releases results from trials on its breast cancer drugs camizestrant and capivasertib, both when compared to faslodex, which treats breast cancer.
The Cambridge-based pharmaceutical company said a phase II trial, camizestrant significantly delayed disease progression in advanced ER-positive breast cancer, adding a benefit of at least 3.5 months when compared to treatment with faslodex.
The ‘meaningful’ improvement in progression-free survival showed at both 75 milligram and 150 milligram doses. The reduction was 42% at a 75 mg dose and 33% at a 150 mg dose, delaying disease progression for the 75 mg dosage to 7.2 months from 3.7 months, and in the 150 mg dosage to 7.7 months from 3.7 months.
In a subgroup of patients with ESR1 mutations, which were 37% of the trial population, the reduction via camizestrant was 67% at a 75 mg dose and 45% at a 150 mg dose.
Meanwhile, in a phase III trial, AstraZeneca’s other breast cancer drug capivasertib showed a 40% reduction in risk of disease progression when combined with faslodex, compared to a placebo plus Faslodex.
Susan Galbraith, executive vice president of AstraZeneca’s Oncology research & development arm, said: ‘Capivasertib brings important progress to an area with persistent treatment gaps as the first therapy of its kind shown to be effective in a Phase III trial in patients with advanced HR-positive, HER2-low or negative breast cancer. We believe these results which showed benefit in all-comers and biomarker positive populations can reshape HR-positive breast cancer treatment, and that capivasertib can become an important new option for patients.’
AstraZeneca shares were 0.4% higher at 11,300.00 pence each on Thursday afternoon in London.
By Tom Budszus, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2022 Alliance News Ltd. All Rights Reserved.
|
